<DOC>
	<DOCNO>NCT01574131</DOCNO>
	<brief_summary>The purpose study learn follow : whether long-term treatment ( 6 month ) fenofibrate decrease burn relate sugar fat increase blood help prevent muscle loss improve wound healing .</brief_summary>
	<brief_title>Acute Long-Term Outcome Investigations Fenofibrate Severely Burned Patients</brief_title>
	<detailed_description>Following severe burn injury human patient mitochondrial fat oxygenation capacity decrease muscle . This associated correspond progression severity resistance action insulin glucose disposal protein synthesis breakdown muscle , regenerate wound liver . Fatty acid active intracellular product ( e.g . DAG , acyl- Coenzyme A ( CoA ) acylcarnitine ) direct inhibitor insulin action , rather tissue triglyceride ( TG ) . In word , impaired mitochondrial fatty acid oxygenation mechanism cause altered lipid metabolism ultimately contribute insulin resistance . Accumulation active fatty acid product , DAG , acyl-CoA acylcarnitine ester muscle cell due rate uptake plasma free fatty acid ( FFA ) exceed rate oxygenation within muscle due principally reduce capacity mitochondrion oxidize fatty acid . Decreasing insulin sensitivity muscle relate impaired insulin signal . This reflect increased activity protein kinase C ( PKC ) . Because PKC think exert regulatory effect primarily either tyrosine kinase activity insulin receptor downstream kinase insulin receptor substrate ( IRS ) phosphorylation , element insulin signal cascade decrease . In turn , element insulin signal relate response muscle glucose ( PI3 Kinase ) protein ( P70S6k ) metabolism reduce . The investigator propose increase tissue PKC activity associate increase tissue concentration DAG , acyl-CoA acylcarnitine . The investigator hypothesize treatment patient peroxisome proliferator-activated receptor ( PPAR ) alpha antagonist fenofibrate improve mitochondrial capacity oxidize fatty acid . Insulin sensitivity muscle , skin liver term glucose protein metabolism improved fenofibrate treatment .</detailed_description>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>≥40 % Burn age 420years body weight ≥10kg &lt; 40 % burn age &lt; 4 &gt; 20 year body weight &lt; 10kg Respiratory insufficiency Multiple fracture History cancer last 5 year Bilirubin &gt; 3mg/dL Serum Creatinine &gt; 3mg/dL fluid resuscitation GlutamylOxaloacetic Transaminase ( GOT ) &gt; 40 Units/L GlutamylPyruvate Transminase ( GPT ) &gt; 51 Units/L Associated head injury require therapy Associated injury chest abdomen require surgery Receipt experimental drug one supply within two month study Any metal body include rod , neurofibrilators , pacemaker , etc Orthopedic cast would prevent placement MRI Hepatitis Abnormal EKG Electrical burn</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Burn</keyword>
	<keyword>Fenofibrate</keyword>
	<keyword>PPAR alpha agonist</keyword>
	<keyword>insulin sensitivity</keyword>
	<keyword>mitochondrial</keyword>
</DOC>